Debiopharm and Mepha Sign Distribution Agreement for Pamorelin(R) LA

May 11, 2009
    LAUSANNE and AESCH, Switzerland, May 11 /PRNewswire/ --
    - 1- 3- and 6-Month Formulations
    - A new Treatment for Prostate Cancer Patients in Switzerland

Debiopharm Group (Debiopharm), a global biopharmaceutical development
specialist that focuses on serious medical conditions, particularly in the
field of oncology, and Mepha Pharma A.G. (Mepha), announce the signature of
an exclusive distribution agreement in Switzerland, for the 1- ,3- and 6
month formulations of Pamorelin(R) LA. The product, which contains the active
substance triptorelin pamoate, is indicated for the treatment of prostate
cancer, endometriosis, and female infertility. Developed by Debiopharm,
Pamorelin(R) LA is being manufactured at Debio R.P. in Martigny, the
Company’s research, development and production facility inspected by
Swissmedic and the United States (U.S.) Food and Drug Administration (FDA).

Andreas Bosshard, CEO of Mepha, Rolland-Yves Mauvernay, President and Founder
of Debiopharm Group and Bertrand Ducrey, CEO of Debio R.P. met in Martigny on
the 8th of May for a high-level kick-off meeting. The launch of Pamorelin(R)
LA in Switzerland is expected in mid-2009.

“We are pleased that Mepha has recognised the added value and comfort
that Pamorelin(R) LA will provide for prostate cancer patients in
Switzerland,” said Rolland-Yves Mauvernay. “We look forward to launching our
product with an experienced Swiss company like Mepha, who has proven
expertise in the commercialisation of high quality products.”

“We are happy to be working alongside an innovative drug developer like
Debiopharm for the distribution of Pamorelin(R) LA in Switzerland. This is
concurrent to our existing innovative drug-line,” added Andreas Bosshard.

About Pamorelin(R) LA

Triptorelin, a luteinizing hormone releasing hormone (LHRH) agonist, was
licensed-in from Tulane University, in 1982. Debiopharm developed and
submitted a 1- and 3-month sustained release formulation of triptorelin
pamoate in Europe and the U.S. These formulations of the product are now
marketed worldwide under the names Trelstar(R) in the U.S. and Decapeptyl(R)
/ Pamorelin(R) in Europe, for the treatment of advanced prostate cancer,
endometriosis, precocious puberty, in-vitro fertilisation programs, and
uterine fibroids.

Debiopharm has also developed a 6-month formulation of triptorelin, which
has been submitted to the European and the U.S. regulatory authorities and
will be submitted to Swissmedic in Q3 2009.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist
that in-licenses promising biological and small molecule drug candidates. It
develops its products for global registration and maximum commercial
potential. Once registered, the products are out-licensed to pharmaceutical
partners for sales and marketing. Debiopharm independently funds the
worldwide development of all of its products while providing expertise in
pre-clinical and clinical trials, manufacturing, drug delivery and
formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm
has developed three products with global combined sales of $2.6 billion in

Debio R.P., is a pharmaceutical research, development and production
facility inspected by the FDA and Swissmedic. Each year, 300’000 patients
worldwide are treated with products that are developed or produced there,
with a response rate to treatment of 95%. Debio R.P. is part of Debiopharm
Group and employs 120 people, of whom half have university or engineering

For more information on Debiopharm Group, please visit:

About Mepha

Mepha is the leading company in the Swiss generic market and is strongly
present in all distribution channels (pharmacists, medical doctors,
hospitals). Mepha develops and produces attractive medical products and
services in Switzerland to enable doctors and pharmacists to treat their
patients with high effectiveness and cost awareness. This is achieved by
Mepha’s highly motivated employees and innovative spirit, examples of which
are as follows. Mepha’s innovative galenics are more readily accepted by
patients, so the patient compliance is higher, which makes for a more
effective treatment. Mepha exports its pharmaceuticals to more than 50
countries, such as the Baltic States, Poland, Portugal in Europe, to Middle
countries, to West and East-Africa and to Southern and Central America.

    Debiopharm S.A. Contact:
    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel.: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69

    Debio R.P. Contact:
    Bertrand Ducrey
    Tel. : +41(0)27-721-79-00
    Fax : +41(0)27-721-79-01
    Email : bducrey@debiopharm.ch

    Mepha Contact:
    Mepha Pharma AG
    Christoph Herzog
    Head of corporate communication
    Tel: +41(0)61-705-44-71
    Fax: +41(0)61-705-42-33
    Email: christoph.herzog@mepha.ch

    Additional Media Contacts
    In London
    Brian Hudspith
    Tel: +44(0)20-7379-5151

    In New York
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel: +1-212-845-4292
    Fax: +1-212-845-4260

SOURCE The Debiopharm Group

Source: newswire

comments powered by Disqus